Investigation of 9 Consecutive Infusions of Remicade for Psoriatic Arthritis in Austria (Study P04264)

Overview

This is a prospective, open-label, 1-arm, multicenter observational study to determine the dose and time interval of Remicade (Infliximab) infusions in psoriatic arthritis (PsA).

Full Title of Study: “Remicade Therapy in Psoriatic Arthritis: Investigation of Real Life Regimen in Austria Over 9 Consecutive Infusions”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: July 2010

Detailed Description

This study population was chosen from a non-probability sample.

Interventions

  • Biological: Remicade (Infliximab)
    • Induction infusions of Remicade will be administered at weeks 0, 2, and 6 given in a dosage due to the decision of the physicians. A maximum of 6 maintenance infusions will be administered with the dosage and interval due to the discretion of the physicians.

Arms, Groups and Cohorts

  • Remicade (Infliximab)
    • Participants with active and progressive PsA who have responded inadequately to disease-modifying anti-rheumatic drugs will receive induction infusions of Remicade at weeks 0, 2, and 6 given in a dosage due to the decision of the physicians. A maximum of 6 maintenance infusions will be administered with the dosage and interval due to the discretion of the physicians. Whole observation period cannot exceed 102 weeks per participant if the maximal therapy interval of 16 weeks as defined in the Summary of Product Characteristics (SPC) is taken into consideration.

Clinical Trial Outcome Measures

Primary Measures

  • Mean Time Interval Between Infusions During Maintenance Therapy
    • Time Frame: Up to 24 months
    • The mean time interval measured in days between Infliximab infusions in participants during the maintenance therapy (between infusion 3/4, 4/5, 5/6, 6/7, 7/8, 8/9) following induction therapy.
  • Median Time Interval Between Infusions During Maintenance Therapy
    • Time Frame: Up to 24 months
    • The median time interval measured in days between Infliximab infusions in participants during the maintenance therapy (between infusion 3/4, 4/5, 5/6, 6/7, 7/8, 8/9) following induction therapy.
  • Average Dose During Induction Therapy and Subsequent Maintenance Therapy
    • Time Frame: Up to 24 Months
    • The average dose per infusion measured in milligrams/killogram (mg/kg) in participants receiving induction therapy and subsequent maintenance therapy (Infusions 1-3 were induction therapy and infusions 4-9 were maintenance therapy for a total of 9 consecutive infusions).
  • Median Dose During Induction Therapy and Subsequent Maintenance Therapy
    • Time Frame: Up to 24 Months
    • The median dose per infusion measured in mg/kg in participants receiving induction therapy and subsequent maintenance therapy (Infusions 1-3 were induction therapy and infusions 4-9 were maintenance therapy for a total of 9 consecutive infusions).
  • Average Overall Dose of All Infusions Per Participant
    • Time Frame: Up to 24 Months
    • The average overall dose of all infusions among all Infliximab-naive participants measured in mg/kg.
  • Median Dose of All Infusions Per Participant
    • Time Frame: Up to 24 Months
    • The median dose of all infusions among all Infliximab-naive participants measured in mg/kg.

Participating in This Clinical Trial

Inclusion Criteria

  • Participants with active and progressive psoriatic arthritis who have responded inadequately to disease-modifying anti-rheumatic drugs. Exclusion Criteria:

  • All according to contraindications in the label especially: – Participants with tuberculosis or other severe infections such as sepsis, abscesses, and opportunistic infections. – Participants with moderate or severe heart failure (NYHA class III/IV). – Participants with a history of hypersensitivity to infliximab or to other murine proteins, or to any of the excipients.

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Merck Sharp & Dohme LLC
  • Collaborator
    • Centocor, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.